Everolimus

Drug Profile

Everolimus

Alternative Names: Absorb; Affinitor; Affinitor Dispersible; Afinitor; Afinitor Disperz; Certican; Esprit BVS; Promus; Promus Element; Promus Premier; RAD; RAD-001; SDZ RAD; Synergy; Votubia; Xience nano; Xience Prime; Xience V; Xience Xpedition; Zortress

Latest Information Update: 27 Mar 2017

Price : $50

At a glance

  • Originator Novartis; University of Michigan Comprehensive Cancer Center
  • Developer Abbott Laboratories; Assistance Publique Hopitaux de Paris; Boston Scientific Corporation; Dana-Farber Cancer Institute; Hannover Medical School; Italian Trials in Medical Oncology; National Cancer Institute (USA); New York University School of Medicine; Novartis; Sarcoma Alliance for Research through Collaboration; SCRI Development Innovations; University of California at San Francisco; University of Sydney; University of Texas M. D. Anderson Cancer Center; Yale University
  • Class Antineoplastics; Macrolides; Polyenes
  • Mechanism of Action B cell inhibitors; Immunosuppressants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Astrocytoma; Angiomyolipoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angiomyolipoma; Astrocytoma; Breast cancer; Coronary artery restenosis; Heart transplant rejection; Kidney disorders; Liver transplant rejection; Neuroendocrine tumours; Renal cell carcinoma; Renal transplant rejection
  • Registered Partial epilepsies
  • Phase III Autosomal dominant polycystic kidney disease; Hepatocellular carcinoma; Myocardial infarction
  • Phase II Cognition disorders; Endometrial cancer; Endometrial hyperplasia; Germ cell and embryonal neoplasms; Glioma; Head and neck cancer; Hodgkin's disease; Neurofibromatoses; Neurofibromatosis 2; Non-small cell lung cancer; Pancreatic cancer; Plexiform neurofibroma
  • Phase I/II Acute lymphoblastic leukaemia; Colorectal cancer; Oesophageal cancer
  • Phase I Cervical cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Prostate cancer; Solid tumours; Tuberous sclerosis
  • No development reported Mantle-cell lymphoma; Mesothelioma
  • Discontinued Diffuse large B cell lymphoma; Gastric cancer; Gastrointestinal stromal tumours; Pulmonary fibrosis; Rheumatoid arthritis

Most Recent Events

  • 13 Feb 2017 The Scottish Medicines Consortium recommended the use of everolimus for the treatment of Neuroendocrine tumours of gastrointestinal or lung origin in adults
  • 31 Jan 2017 Registered for Partial epilepsies (In adolescents, In children, In adults) in Norway, Liechtenstein, Iceland, European Union (PO)
  • 27 Jan 2017 Discontinued - Phase-III for Diffuse large B cell lymphoma (Second-line therapy or greater, Adjuvant therapy) in Argentina, Austria, Egypt, Colombia, Canada, Japan, Israel, Germany, Hong Kong, Russia, Singapore, Spain, Lebanon, Peru, New Zealand, Thailand, Venezuela, Australia, Brazil, Czech Republic, China, Italy, Hungary, France, Greece, Poland, Saudi Arabia, Slovakia, South Korea, Mexico, Norway, Switzerland, Turkey, USA (PO) (Novartis 20-F 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top